Dolutegravir / rilpivirine

Details

Files
Generic Name:
Dolutegravir rilpivirine
Project Status:
Complete
Therapeutic Area:
HIV infection
Manufacturer:
ViiV Healthcare ULC
Call for patient/clinician input open:
Brand Name:
Juluca
Project Line:
Reimbursement Review
Project Number:
SR0551-000
Call for patient/clinician input closed:
Performance Metric:
Achieved
Biosimilar:
No
Submission Type:
Initial
Fee Schedule:
Schedule A
Indications:
HIV infection
Recommendation Type:
Reimburse with clinical criteria and/or conditions
Final Recommendation:

Key Milestones2

Call for patient input postedNovember 23, 2017
Patient group input closedJanuary 19, 2018
Clarification:

- Patient input submission received

Patient input summary sent for review to patient input groupsJanuary 30, 2018
Patient group comments on input summary closedFebruary 06, 2018
Clarification:

- Patient input summary feedback received

Submission receivedDecember 21, 2017
Submission accepted for reviewJanuary 12, 2018
Review initiatedJanuary 15, 2018
Draft CDR review report(s) sent to applicantMarch 29, 2018
Comments from applicant on draft CDR review report(s) receivedApril 10, 2018
Redaction requests from applicant on draft CDR review report(s) receivedApril 17, 2018
CDR review team's comments on draft CDR review report(s) sent to applicantMay 04, 2018
Canadian Drug Expert Committee (CDEC) meetingMay 16, 2018
CDEC recommendation & redacted CDR review report(s) sent to applicant and drug plansMay 30, 2018
Embargo period ended and validation of redacted CDR review report(s) receivedJune 13, 2018
CDEC Final Recommendation issued to applicant and drug plansJune 20, 2018
CDEC Final Recommendation postedJune 22, 2018
Final CDR review report(s) and patient input postedJune 22, 2018